|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baade PD, Youlden DR, Cramb SM, Dunn J and
Gardiner RA: Epidemiology of prostate cancer in the Asia-Pacific
region. Prostate Int. 1:47–58. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Freedland SJ: Screening, risk assessment
and the approach to therapy in patients with prostate cancer.
Cancer. 117:1123–1135. 2011. View Article : Google Scholar
|
|
4
|
Taiakina D, Dal Pra A and Bristow RG:
Intratumoral hypoxia as the genesis of genetic instability and
clinical prognosis in prostate cancer. Adv Exp Med Biol.
772:189–204. 2014. View Article : Google Scholar
|
|
5
|
Voss MJ, Niggemann B, Zänker KS and
Entschladen F: Tumour reactions to hypoxia. Curr Mol Med.
10:381–386. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jones BA, Beamer M and Ahmed S:
Fractalkine/CX3CL1: A potential new target for inflammatory
diseases. Mol Interv. 10:263–270. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lucas AD, Bursill C, Guzik TJ, Sadowski J,
Channon KM and Greaves DR: Smooth muscle cells in human
atherosclerotic plaques express the fractalkine receptor CX3CR1 and
undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1).
Circulation. 108:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Blaschke S, Koziolek M, Schwarz A, Benöhr
P, Middel P, Schwarz G, Hummel KM and Müller GA: Proinflammatory
role of fractalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol.
30:1918–1927. 2003.PubMed/NCBI
|
|
9
|
Tang L, Hu HD, Hu P, Lan YH, Peng ML, Chen
M and Ren H: Gene therapy with CX3CL1/Fractalkine induces antitumor
immunity to regress effectively mouse hepatocellular carcinoma.
Gene Ther. 14:1226–1234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Faure S, Meyer L, Costagliola D,
Vaneensberghe C, Genin E, Autran B, Delfraissy JF, McDermott DH,
Murphy PM, Debré P, et al: Rapid progression to AIDS in HIV+
individuals with a structural variant of the chemokine receptor
CX3CR1. Science. 287:2274–2277. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ludwig A, Hundhausen C, Lambert MH,
Broadway N, Andrews RC, Bickett DM, Leesnitzer MA and Becherer JD:
Metalloproteinase inhibitors for the disintegrin-like
metalloproteinases ADAM10 and ADAM17 that differentially block
constitutive and phorbol ester-inducible shedding of cell surface
molecules. Comb Chem High Throughput Screen. 8:161–171. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jamieson WL, Shimizu S, D'Ambrosio JA,
Meucci O and Fatatis A: CX3CR1 is expressed by prostate epithelial
cells and androgens regulate the levels of CX3CL1/fractalkine in
the bone marrow: Potential role in prostate cancer bone tropism.
Cancer Res. 68:1715–1722. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nevo I, Sagi-Assif O, Meshel T, Ben-Baruch
A, Jöhrer K, Greil R, Trejo LE, Kharenko O, Feinmesser M, Yron I
and Witz IP: The involvement of the fractalkine receptor in the
transmigration of neuroblastoma cells through bone-marrow
endothelial cells. Cancer Lett. 273:127–139. 2009. View Article : Google Scholar
|
|
14
|
Erreni M, Solinas G, Brescia P, Osti D,
Zunino F, Colombo P, Destro A, Roncalli M, Mantovani A, Draghi R,
et al: Human glioblastoma tumours and neural cancer stem cells
express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer.
46:3383–3392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shulby SA, Dolloff NG, Stearns ME, Meucci
O and Fatatis A: CX3CR1-fractalkine expression regulates cellular
mechanisms involved in adhesion, migration and survival of human
prostate cancer cells. Cancer Res. 64:4693–4698. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu Y, Cai Z, Galson DL, Xiao G, Liu Y,
George DE, Melhem MF, Yao Z and Zhang J: Monocyte chemotactic
protein-1 (MCP-1) acts as a paracrine and autocrine factor for
prostate cancer growth and invasion. Prostate. 66:1311–1318. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiao LJ, Chen YY, Lin P, Zou HF, Lin F,
Zhao LN, Li D, Guo L, Tang JB, Zheng XL and Yu XG: Hypoxia
increases CX3CR1 expression via HIF-1 and NFκB in
androgen-independent prostate cancer cells. Int J Oncol.
41:1827–1836. 2012.PubMed/NCBI
|
|
18
|
Xiao LJ, Lin P, Lin F, Liu X, Qin W, Zou
HF, Guo L, Liu W, Wang SJ and Yu XG: ADAM17 targets MMP-2 and MMP-9
via EGFR-MEK-ERK pathway activation to promote prostate cancer cell
invasion. Int J Oncol. 40:1714–1724. 2012.
|
|
19
|
Hasegawa M, Sato S, Echigo T, Hamaguchi Y,
Yasui M and Takehara K: Up regulated expression of
fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis.
Ann Rheum Dis. 64:21–28. 2005. View Article : Google Scholar
|
|
20
|
Harbour JW, Luo RX, Dei Santi A, Postigo
AA and Dean DC: Cdk phosphorylation triggers sequential
intramolecular interactions that progressively block Rb functions
as cells move through G1. Cell. 98:859–869. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
22
|
Nishimura S, Hato M, Hyugaji S, Feng F and
Amano M: Glycomics for drug discovery: Metabolic perturbation in
androgen-independent prostate cancer cells induced by unnatural
hexosamine mimics. Angew Chem Int Ed Engl. 51:3386–3390. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feldman BJ and Feldman D: The development
of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45.
2001. View
Article : Google Scholar
|
|
24
|
Borsig L, Wolf MJ, Roblek M, Lorentzen A
and Heikenwalder M: Inflammatory chemokines and metastasis-tracing
the accessory. Oncogene. 33:3217–3224. 2013. View Article : Google Scholar
|
|
25
|
Waugh DJ, Wilson C, Seaton A and Maxwell
PJ: Multi-faceted roles for CXC-chemokines in prostate cancer
progression. Front Biosci. 13:4595–4604. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang S, Qi L, Li M, Zhang D, Xu S, Wang N
and Sun B: Chemokine CXCL12 and its receptor CXCR4 expression are
associated with perineural invasion of prostate cancer. J Exp Clin
Cancer Res. 27(62)2008. View Article : Google Scholar
|
|
27
|
Wang J, Lu Y, Wang J, Koch AE, Zhang J and
Taichman RS: CXCR6 induces prostate cancer progression by the
AKT/mammalian target of rapamycin signaling pathway. Cancer Res.
68:10367–10376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bazan JF, Bacon KB, Hardiman G, Wang W,
Soo K, Rossi D, Greaves DR, Zlotnik A and Schall T: A new class of
membrane-bound chemokine with a CX3C motif. Nature. 385:640–644.
1997. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Koch AE: Chemokines and their receptors in
rheumatoid arthritis: Future targets? Arthritis Rheum. 52:710–721.
2005. View Article : Google Scholar
|
|
30
|
Rimaniol AC, Till SJ, Garcia G, Capel F,
Godot V, Balabanian K, Durand-Gasselin I, Varga EM, Simonneau G,
Emilie D, et al: The CX3C chemokine fractalkine in allergic asthma
and rhinitis. J Allergy Clin Immunol. 112:1139–1146. 2003.
View Article : Google Scholar
|
|
31
|
Foussat A, Bouchet-Delbos L, Berrebi D,
Durand-Gasselin I, Coulomb-L'Hermine A, Krzysiek R, Galanaud P,
Levy Y and Emilie D: Deregulation of the expression of the
fractalkine/frac-talkine receptor complex in HIV-1-infected
patients. Blood. 98:1678–1686. 2001. View Article : Google Scholar
|
|
32
|
Muehlhoefer A, Saubermann LJ, Gu X,
Luedtke-Heckenkamp K, Xavier R, Blumberg RS, Podolsky DK,
MacDermott RP and Reinecker HC: Fractalkine is an epithelial and
endothelial cell-derived chemoattractant for intraepithelial
lymphocytes in the small intestinal mucosa. J Immunol.
164:3368–3376. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Blum DL, Koyama T, M'Koma AE, Iturregui
JM, Martinez-Ferrer M, Uwamariya C, Smith JA Jr, Clark PE and
Bhowmick NA: Chemokine markers predict biochemical recurrence of
prostate cancer following prostatectomy. Clin Cancer Res.
14:7790–7797. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu X, Wang Y, Chen J, Ma H, Shao Z, Chen H
and Jin G: High expression of CX3CL1/CX3CR1 axis predicts a poor
prognosis of pancreatic ductal adenocarcinoma. J Gastrointest Surg.
16:1493–1498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gaudin F, Nasreddine S, Donnadieu AC,
Emilie D, Combadière C, Prévot S, Machelon V and Balabanian K:
Identification of the chemokine CX3CL1 as a new regulator of
malignant cell proliferation in epithelial ovarian cancer. PloS
one. 6:e215462011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: A review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Malumbres M and Carnero A: Cell cycle
deregulation: A common motif in cancer. Prog Cell Cycle Res.
5:5–18. 2003.PubMed/NCBI
|
|
38
|
Golias CH, Charalabopoulos A and
Charalabopoulos K: Cell proliferation and cell cycle control: A
mini review. Int J Clin Pract. 58:1134–1141. 2004. View Article : Google Scholar
|
|
39
|
White GE, Tan TC, John AE, Whatling C,
McPheat WL and Greaves DR: Fractalkine has anti-apoptotic and
proliferative effects on human vascular smooth muscle cells via
epidermal growth factor receptor signalling. Cardiovasc Res.
85:825–835. 2010. View Article : Google Scholar :
|
